(INDP) Indaptus Therapeutics, Inc. Business Model Canvas Research

Regulatory and clinical advisors help Indaptus Therapeutics, Inc. turn its oncology and antiviral programs into FDA-ready plans, from IND strategy to trial design and agency meetings. They reduce missteps in a field where one bad protocol can delay a first-in-human study by months.

• Guide IND filings and FDA touchpoints
• Shape oncology and antiviral trial design
• Keep plans aligned with agency expectations

Academic and translational research collaborators help Indaptus Therapeutics validate Decoy20 across 2 disease areas: cancer and viral infections. They can run biomarker, mechanism, and translational studies, which helps build a stronger evidence package for efficacy and dose selection.

• Supports biomarker readouts
• Deepens mechanism studies
• Strengthens Decoy20 data

For Indaptus Therapeutics, Inc., trial design and data analysis are the core engine in early-stage oncology and antiviral work: the company must run tight, dose-escalation protocols and read safety data fast because there is no approved product revenue yet. In 1st-in-human studies, every cohort can change the next dose, expansion plan, and go/no-go call.

• Design tight early-phase protocols.
• Track safety signals in real time.
• Measure response trends across cohorts.
• Guide dose escalation and next steps.

Regulatory preparation is a core key activity for Indaptus Therapeutics, Inc. because every clinical asset needs constant IND maintenance, safety reporting, and trial submissions to keep studies moving. In 2025, that work mattered as a cash-burn biotech task: timely filings help avoid pauses, data holds, and lost trial time.

• Maintain IND files and amendments
• Report safety events fast
• Submit trial updates on time
• Protect uninterrupted clinical progress

Indaptus Therapeutics, Inc. lists New York, New York as its headquarters and central operating base. It supports administration, strategy, and investor-facing work, which matters for a lean biotech model that runs most R&D through partners and external sites.

• New York, New York HQ
• Admin and strategy hub
• Investor-facing base

Biotech value creation depends on experienced management and board oversight because they decide how limited capital is split across financing, clinical milestones, and strategy. For a development-stage Company Name, governance is a key resource that helps keep trial plans, cash use, and partner talks aligned.

• Steers financing and runway
• Prioritizes clinical programs
• Supports strategy and risk control

Decoy20 broadens Indaptus Therapeutics, Inc.’s value proposition by spanning 6 active disease areas: lymphoma, hepatocellular, colorectal, pancreatic, hepatitis B, and HIV. One molecule can feed a wider pipeline, which lowers single-asset risk and raises the odds of a usable clinical win.

• 6 indication paths
• 1 molecule, wider reach
• Less single-asset risk

Indaptus Therapeutics, Inc. is testing its candidate in combination with other treatments, because combo regimens in oncology often lift response rates and can reach more patients than a single agent alone. This matters in a market where most approved cancer drugs are used with partners, and combination therapy remains a core value driver for new oncology assets.

• Boosts efficacy in mixed tumors
• Can widen patient response rates
• Fits standard oncology development

Indaptus Therapeutics, Inc. must keep formal, tightly controlled regulator contact through FDA and other agencies across clinical work, with compliant filings, safety reports, and protocol updates. This relationship is rule-heavy and time-sensitive, because even one missed submission can slow trial progress.

• Structured regulator talks
• Compliant filings and safety reports
• High control, low flexibility

Potential collaborators need access to Indaptus Therapeutics, Inc. data, study plans, and milestone gates, because biotech partnering is evidence-driven and usually tied to clear proof points. That setup supports future licensing or co-development talks, where each step can be priced to results and risk.

• Share data and plans early
• Use milestone-based partner terms
• Build toward licensing options

Indaptus Therapeutics, Inc.’s corporate website is a direct, low-cost channel for investors, partners, and job seekers. It can host pipeline updates, governance docs, and press releases in one place, which matters for a micro-cap biotech with no product sales and 2025 revenue of $0.

• Direct access to pipeline and governance
• Low-cost, always-on stakeholder reach
• Fits a pre-revenue biotech model

Regulatory submissions are Indaptus Therapeutics, Inc.’s formal channel to the FDA for INDs, protocol amendments, safety reports, and annual updates. An IND usually faces a 30-day FDA review clock, so filings are not optional; they are what let the clinical program start, change, and stay legal.

• IND opens trial access
• Amendments keep studies active
• Safety filings protect legality

Infectious disease specialists are key for Indaptus Therapeutics, Inc. because HBV and HIV care usually runs through specialist clinics, not primary care. WHO says about 254 million people live with chronic HBV and 39.9 million with HIV, so these physicians shape both adoption and trial enrollment.

• Specialist-led HBV and HIV pathways
• Drive clinical adoption and referrals
• Trial participation depends on antiviral clarity

Pharma and biotech partners are key commercial customers for Indaptus Therapeutics, Inc., because they may want access to its novel immunotherapy platform or a combo asset for oncology. This segment is important for licensing and co-development, where deals often hinge on platform validation, with biotech partnering transactions commonly carrying upfront cash, milestones, and royalties.

• Targets licensing and co-development
• Seeks novel immunotherapy access
• Can support milestone-based deal value

Regulatory and compliance costs are non-discretionary for Indaptus Therapeutics, Inc.: clinical-stage biotechs must fund FDA filings, safety reporting, and quality systems, while legal and regulatory support stays on the clock. As a real benchmark, the FDA FY2026 human drug application fee is $4,240,900, showing how quickly compliance spend can become material.

• IND, safety, and quality work never stop
• External legal support adds fixed overhead
• Fees and reporting can dwarf early revenue

General and administrative costs stay high for Indaptus Therapeutics, Inc. because headquarters, management, finance, legal, and SEC reporting are all ongoing public-company costs. Being based in New York also tends to lift office and labor expense, so this cost line usually stays fixed even when R&D shifts.

• Headquarters and admin are recurring.
• Public reporting adds SEC overhead.
• New York raises operating costs.

Indaptus Therapeutics can turn strategic partnerships into upfront cash and milestone income, with payments typically linked to development or regulatory steps. In biotech, these deals often fund R&D before product sales start, but Indaptus has not shown this as a core revenue source in recent filings, so it remains a deal-driven option.

• Upfront fees can fund early trials.
• Milestones follow study or FDA wins.
• Partnering is common in biotech.

Indaptus Therapeutics, Inc. is still in a pre-revenue stage, so research grants or other non-dilutive support would be a small, supplemental cash source rather than a core revenue stream. For early-stage biotech, these funds can help pay for preclinical and translational work without adding shareholder dilution.

• Supplemental, not primary, funding
• Covers preclinical and translational costs
• Reduces equity dilution pressure